A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Oral Suberoylanilide Hydroxamic Acid (L-001079038) in Patients With Advanced Malignant Pleural Mesothelioma Previously Treated With Systemic Chemotherapy

Registry ID

EUCTR2005-000949-11

Source registry

EUCTR

Status

Prematurely Ended

Phase

PHASE3

Sponsor

Merck Sharp & Dohme (Sweden) AB

Start date

2005-06-22

Last update

2026-08-16

Conditions

• trattamento del mesotelioma pleurico maligno avanzato resistente al trattamento con penetrexed/sale di platino
• Mesothelioma
• Advanced Malignant Pleural Mesothelioma previously treated with systemic chemotherapy.
• Mesotelioma

Summary

To compare the overall survival associated with L-001079038 plus best supportive care versus that associated with placebo plus best supportive care for the treatment of patients with advanced malignant pleural mesothelioma who have failed prior chemotherapy that has included pemetrexed in combination with either cisplatin or carboplatin, and to determine the overall safety and toxicity of L-001079038 in this population

Locations

• , , Belgium
• , , Sweden
• , , Greece
• , , Spain
• , , UK
• , , Germany
• , , Italy
• , , Portugal

Related clinical trials

• Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome
• Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
• Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1
• A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
• Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
• A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

View on source registry